The Multiple Myeloma and Proteasome Inhibitors module has been designed to provide you with an understanding of multiple myeloma and the therapies used in its treatment, with a focus on proteasome inhibitor therapies. This module also describes the role of nurses in managing patients with multiple myeloma and how they can support patients going through therapy.
We have developed this module to provide useful tools and resources to help you support your multiple myeloma cancer patients throughout their journey.
Please see our disclaimer regarding module content.
This e-learning module will take 60 minutes. Optional pre-reading, available in the ‘resources’ section of this page, will take approximately 30–60 minutes. Saving where you left off, you can dip in and out of the module whenever you have the time. You are encouraged to make notes or take screenshots during the module to reinforce your learning.
This module is accredited by the Royal College of Nursing (RCN). The RCN cannot confirm the competence of any practitioner. You will receive a certificate via email for your one hour of learning upon completion.
Nurses play a key role in the provision of care to patients who have been diagnosed with multiple myeloma, supporting them through their various treatment therapies.
* Save your place and obtain CME credits.
† Your place will not be saved.
Erik Aerts is President of the Scientific Committee of the Haematology Nurses & Healthcare Professionals Group.
Barry Quinn PhD, MSc, PG Cert Teaching, BD, Bacc Phil, RN Director of Nursing for Cancer and Palliative Care/Senior Lecturer Barts Health NHS Trust, London, United Kingdom.
This independent educational activity is supported by an educational grant provided by Amgen. PCM Scientific is the medical education company acting as scientific secretariat and organiser for this programme. The activity is run independently of the financial supporter and all content is created by the faculty. No funder has had input into the content of the activity.